In a welcome move, Blueprint Medicines saw its Relative Strength Rating improve from 66 to 78 on Monday.
Can You Really Time The Stock Market?
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks compares to other publicly traded companies.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest climbs. See if Blueprint Medicines can continue to rebound and clear that threshold.
Blueprint Medicines is not currently offering a proper buying opportunity. See if the stock goes on to form a base that could ignite a new run.
Blueprint Medicines reported -99% earnings growth in the latest quarterly report, while sales growth came in at 55%.
The company earns the No. 101 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
